Home   Chapter Home   Jobs   Conferences   Fellowships   Books



Advertisement

Stains

Programmed death-1 (PD-1)


Reviewer: Nat Pernick, M.D. (see Reviewers page)
Revised: 17 May 2012, last major update May 2012
Copyright: (c) 2002-2012, PathologyOutlines.com, Inc.

Definition
=========================================================================

● Also known as CD279
● Co-inhibitory receptor of lymphocytes / other immune system cells; controls lymphocyte activation by providing negative signals in conjunction with signals from lymphocyte antigen receptors (Future Oncol 2011;7:929)
● Expressed by germinal center-associated helper T cells; inhibits T cell activity (Hum Pathol 2009;40:1715)
● Expressed by CD8+ T cells, associated with CD8 activation (AIDS Res Hum Retroviruses 2012;28:465)
● Has two known ligands: PD-L1 (B7H1; CD274) and PD-L2 (B7DC; CD273)
● May limit CNS inflammation and neurologic deficits after stroke (Stroke 2011;42:2578)

Uses by pathologists
=========================================================================

● Differentiate primary cutaneous CD4 small/medium-sized pleomorphic T-cell lymphoma and cutaneous pseudo-T-cell lymphomas (PD-1 positive) from other cutaneous T cell lymphomas (usually PD-1 negative, Am J Surg Pathol 2012;36:109)
● PD-1+ rosettes of T cells around neoplastic cells is relatively specific for nodular lymphocyte-predominant Hodgkin lymphoma (Hum Pathol 2009;40:1715)

Micro images
=========================================================================



Normal tonsil


Normal bone marrow and bone marrow with angioimmunoblastic lymphoma


Esophageal carcinoma: PD-L1 and PD-L2


Lymph nodes: progressive transformation of germinal centers with focus of nodular lymphocyte predominant Hodgkin lymphoma; both are PD-1 positive


Lymph nodes: viral lymphadenitis and Rosai-Dorfman are PD-1 positive


Lymph nodes: reactive conditions that are PD-1 negative

       
Lymphoma: angioimmunoblastic


Lymphoma: nodular lymphocyte predominant Hodgkin lymphoma


Ovarian serous adenocarcinoma: PD-L1 and PD-L2


Pancreatic adenocarcinoma: PD-L1 and PD-L2

Positive staining - normal
=========================================================================

● Pro-B cells
● Germinal center-associated helper T cells

Positive staining - disease
=========================================================================

● Angioimmunoblastic lymphoma (Am J Surg Pathol 2006;30:802)
● CLL/SLL - B cells (Hum Pathol 2008;39:1050)
● Diffuse large B cell lymphoma: T cell and histiocyte rich (33-40%, Hum Pathol 2010;41:1726)
● Hodgkin lymphoma: T cells associated with neoplastic B cells in nodular lymphocyte-predominant Hodgkin lymphoma with classic nodular architecture (87%), decreasing in diffuse areas; lymphocyte-rich classic (33-40%, Hum Pathol 2010;41:1726)
● Primary cutaneous CD4 small/medium-sized pleomorphic T-cell lymphoma; cutaneous pseudo-T-cell lymphoma (Am J Surg Pathol 2012;36:109)
● Progressive transformation of germinal centers, Rosai-Dorfman disease, viral lymphadenitis (EBV and HIV) (Am J Surg Pathol 2010;34:178)

Negative staining
=========================================================================

● Cat-scratch disease, Kikuchi lymphadenitis, Castleman disease, reactive follicular hyperplasia are PD-1 negative outside follicles (Am J Surg Pathol 2010;34:178)

End of Stains > Programmed death-1 (PD-1)

Ref Updated: 4/25/12


This information is intended for physicians and related personnel, who understand that medical information is often imperfect, and must be interpreted in the context of a patient's clinical data using reasonable medical judgment. This website should not be used as a substitute for the advice of a licensed physician.

All information on this website is protected by copyright of PathologyOutlines.com, Inc. Information from third parties may also be protected by copyright. Please contact us at copyrightPathOut@gmail.com with any questions (click here for other contact information).